GlassScriptPhysician profile
Holly A Mast
NPI 1407101728
$1,209.18
in general payments reported to CMS, 2019-2025
20 companies · $249 in 2025
The $249 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $57.76 · 2022: $151 · 2023: $338 · 2024: $414 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,000.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $223.10 | 2022-2025 | |
| Novo Nordisk INC | $132.75 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $123.57 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $113.67 | 2023-2025 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $98.04 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Otsuka America Pharmaceutical, INC. | $70.25 | 2023-2025 | Rexulti |
| Pfizer INC. | $65.42 | 2021-2024 | |
| Lilly USA, LLC | $60.27 | 2023-2024 | Mounjaro |
| Mylan Specialty L.P. | $49.54 | 2021-2023 | Yupelri |
| Astellas Pharma US INC | $47.59 | 2024 | Veozah |
| Exact Sciences Corporation | $36.15 | 2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $33.93 | 2024 | |
| Nestle Healthcare Nutrition INC. | $27.32 | 2022 | |
| Dexcom, INC. | $24.47 | 2023 | Dexcom G6 Transmitter |
| Lundbeck LLC | $21.27 | 2024 | Vyepti |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $20.22 | 2024 | Spravato |
| Glaxosmithkline, LLC. | $18.48 | 2022 | |
| Dynavax Technologies Corporation | $16.56 | 2023 | Heplisav-B |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.72 | 2023 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.86 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Mast listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.